The inactivation of the EC system through administration of cannabinoid receptor 1 (CB1R) antagonist or CB1R knockout can ameliorate obesity-associated metabolic disorders such as insulin resistance and compensatory hyperinsulinemia and hepatic steatosis. Here, CNR1 is linked to obesity disorder.